28 January
2025
Aptamer
Group plc
("Aptamer", the "Company" or the "Group")
Issue of
Equity in lieu of Director fees
Aptamer Group plc (AIM: APTA), the developer of
novel Optimer® binders to enable innovation in
the life sciences industry, today announces that it has issued
3,499,343 new ordinary shares of 0.1 pence each ("Ordinary Shares")
at an average issue price of 0.2858 pence per Ordinary Share to
settle Non-Executive Director fees.
Director fee
shares
Tim Sykes has agreed to take his
Non-Executive Director fees in shares commencing 1 January 2025.
Shares will be issued to Tim on a quarterly basis in lieu of fees.
Today's share issue will cover the period 1 January 2025 to 31
March 2025. Each quarter, the price of each share issue will be
based on the volume weighted average daily closing share price of
the preceding quarter. For this share issue, that was the period 1
October 2024 to 31 December 2024.
Following this transaction, Tim
Sykes total beneficial interest in the Company is 8,671,063
Ordinary Shares, representing approximately 0.44% of the Company's
issued share capital.
Total voting
rights
Application will be made for the admission of
these shares to trading on AIM, which is expected to become
effective on or about 3 February 2025.
Immediately following Admission the Company
will have 1,991,343,016 Ordinary Shares of £0.001 each in issue.
The Company does not hold any shares in treasury and all of the
Ordinary Shares have equal voting rights. Therefore, the figures
above represent the total voting rights in the Company and may be
used by shareholders as the denominator for the calculations by
which they can determine if they are required to notify their
interest in, or a change to their interest in the Company under the
Rules.
Additional
information
The following disclosures are made in
accordance with the requirements of the UK Market Abuse Regulation
and provide detail in relation to the purchase of Ordinary Shares
by Directors and other PDMRs in the Company.
NOTIFICATIONS AND PUBLIC DISCLOSURE
OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Tim Sykes
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Aptamer Group plc
|
|
b)
|
LEI
|
213800Y4XGH3WJNBE686
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
|
Ordinary shares of £0.001 each
|
|
|
|
|
Identification code
|
GB00BNRRP542
|
|
|
|
|
b)
|
Nature of the transaction
|
Award of shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
0.2858p
|
3,499,343
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
3,499,343
|
|
- Price
|
0.2858p each
|
|
|
|
|
e)
|
Date of the transaction
|
28 January 2025
|
|
f)
|
Place of the transaction
|
Off market
|
- Ends
-
For further information, please
contact:
|
Aptamer Group plc
Arron Tolley,
Chief Executive Officer
|
+44 (0) 1904 217 404
|
|
SPARK Advisory Partners Limited -
Nominated Adviser
Andrew Emmott / Jade
Bayat
|
+44 (0) 20 3368 3550
|
|
Turner Pope Investments (TPI)
Limited - Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657 0050
|
|
Northstar Communications Limited -
Investor Relations
Sarah Hollins
|
+44 (0) 113 730 3896
|
This announcement contains inside
information for the purposes of the UK Market Abuse
Regulation.
About Aptamer Group plc
Aptamer Group is a leading global developer of
aptamer-based ligands that help scientists remove the limits to
discovery and innovation. Leveraging a proprietary discovery and
development platform, Aptamer delivers custom affinity ligands,
supported with a complete suite of characterisation and validatory
assays that enhance the translation of its binders and optimise
scientific outcomes for customers.
Aptamer's cutting-edge technology spans
healthcare, research, personal care, and industrial processes,
delivering new affinity solutions for novel targets, advanced
diagnostics, and precision therapies. By working with industry
leaders in pharmaceutical, biotechnology, personal health,
academic, and clinical research sectors, Aptamer is accelerating
science through the custom development of tools and
therapies.
To register for news alerts by email go
to https://aptamergroup.com/investors/investor-news-email-alerts/.
